Phathom Pharmaceuticals, Inc. Common Stock
Symbol: PHAT (NASDAQ)
0.00
▼ (-100.00%) -12.290
Company Description:
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Key Stats
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $12.29
- Yesterday High: $12.49
- Yesterday Low: $11.78
- Yesterday Volume: 1.95M
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
Company Profile
- Name: Phathom Pharmaceuticals, Inc. Common Stock
- Website: https://www.phathompharma.com
- Listed Date: 2019-10-25
- Location: FLORHAM PARK, NJ
- Market Status: Active
- CIK Number: 0001783183
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $835.01M
- Round Lot: 100
- Outstanding Shares: 70.94M
- Asset Type: CS
RECENT FILINGS FOR PHAT
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-26 | 4 | View |
| 2025-09-09 | 4 | View |
| 2025-08-28 | SCHEDULE 13G/A | View |
| 2025-08-25 | SCHEDULE 13G/A | View |
| 2025-08-20 | SCHEDULE 13D/A | View |
| 2025-08-13 | SCHEDULE 13G | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-07-18 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 3 | View |
| 2025-06-16 | 8-K | View |
| 2025-06-09 | 8-K | View |
| 2025-06-09 | SCHEDULE 13G/A | View |
| 2025-06-06 | 8-K | View |
| 2025-06-06 | SCHEDULE 13G/A | View |
| 2025-06-05 | 4 | View |
| 2025-06-05 | 4 | View |
| 2025-06-05 | 4 | View |
| 2025-06-05 | 4 | View |
Latest News on PHAT